Updated:
MEDTEQ+
MEDTEQ+, led by Alain Beaudoin, has mobilized over CAD 580M into Canadian health-tech ventures since 2012 from its Montreal and Halifax hubs.
MEDTEQ+
MEDTEQ+ was launched in 2012 as the pan-Canadian Consortium for Industrial Research and Innovation in Medical Technologies, with Alain Beaudoin as its founding President and CEO. The firm operates from Montreal and Halifax as a hybrid innovation hub and venture investor, funded through federal and provincial government partnerships alongside private-sector health organizations. Its core mission is to bridge the gap between academic health research and commercial adoption, making it a structurally distinct actor in the Canadian health-tech landscape. The firm deploys capital through a mix of direct venture investments, R&D co-financing, and clinical validation programs that pair startups with established healthcare delivery partners. Its portfolio spans digital health platforms, AI-enabled diagnostics, medical devices, and health-service delivery tools, with confirmed activity across Ontario, Quebec, and the Atlantic provinces. MEDTEQ+ structures its support through repayable and non-repayable contributions alongside equity positions, functioning more like a blended-finance innovation fund than a conventional venture firm. Industry collaborators include major hospital networks and pharmaceutical companies that co-sponsor validation trials. Since inception, MEDTEQ+ has mobilized more than CAD 580 million and supported over 200 health-technology projects, working with a network of more than 100 industrial and institutional partners. It maintains dual hubs in Montreal and Halifax, reflecting a deliberate mandate to serve both central-Canadian and Atlantic innovation clusters. The firm does not report a single AUM figure in the traditional sense, given its blended capital structure. In 2023, MEDTEQ+ continued to expand its investment activity through the federal Strategic Innovation Fund and other public-private co-investment vehicles, reinforcing its role as the dominant health-tech translational fund in Canada. The structural differentiator lies in MEDTEQ+'s operating model: it acts as both investor and clinical matchmaker, formally connecting portfolio companies with university hospitals and provincial health authorities to run real-world validation studies. This dual posture — providing risk capital while organizing the procurement pathway — is uncommon among peers operating in the health sector. The arrangement effectively compresses the timeline between regulatory approval and clinical adoption by embedding the buyer inside the funding process.
General information
Firm type
Asset Manager
Year founded
2012
AUM
$200M–$500M (Altss estimate)
Location
Region
North America
Country
Canada
City
Montreal
Corporate office
Montreal, Quebec, Canada
Additional offices
Halifax, Nova Scotia, Canada
Principals
Alain Beaudoin
President and CEO
Sector focus
Frequently asked questions
Who runs investment decisions at MEDTEQ+?
Investment and partnership decisions are led by President and CEO Alain Beaudoin, who has headed the organization since its 2012 launch. The firm operates through a structured committee process that includes representatives from its government and private-sector funding partners, reflecting its public-private governance model.
How does MEDTEQ+ source proprietary deal flow?
MEDTEQ+ sources opportunities through its network of university-affiliated research hospitals, provincial health authorities, and industry partners who co-sponsor clinical validation projects. This embedded relationship with the healthcare delivery system gives the firm early visibility into technologies emerging from Canadian academic medical centers.
Does MEDTEQ+ participate in fund commitments or only direct deals?
MEDTEQ+ executes direct investments in health-tech companies through a combination of equity positions, repayable contributions, and non-repayable R&D co-financing. The firm does not operate as a fund-of-funds; its capital is deployed directly into operating companies alongside clinical validation support.
What investment stages does MEDTEQ+ typically target?
The firm focuses on pre-seed through Series A stages, emphasizing the translational gap between academic research and commercial viability. Its model is built around de-risking technologies through clinical validation before they require larger institutional venture rounds.
Which sectors does MEDTEQ+ explicitly avoid?
MEDTEQ+ is exclusively focused on health technology, medical devices, and digital health; it does not invest in biotech or pharmaceutical drug development, pure health-services companies without a technology component, or sectors outside healthcare.
How is MEDTEQ+ funded, and where does the underlying capital come from?
MEDTEQ+ is funded through a consortium model combining federal government programs including the Strategic Innovation Fund, provincial economic development agencies, and more than 100 private-sector industrial partners such as hospital networks and pharmaceutical firms, per the firm's official communications. It does not represent a single family's wealth.
Does MEDTEQ+ maintain a presence outside Quebec?
Yes, MEDTEQ+ operates dual hubs in Montreal, Quebec, and Halifax, Nova Scotia, reflecting a deliberate mandate to serve both central-Canadian and Atlantic Canadian health-technology clusters. Its investments span Ontario, Quebec, and the Atlantic provinces.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: